Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: Outcome and prognostic predictors

HPB

Volumn 9, Issue 5, 2007, Pages 345-351

  Gomez, D ^a   Malik, H Z ^a   Al Mukthar, A ^a   Menon, K V ^a   Toogood, G J ^a   Lodge, J P A ^a   Prasad, K R ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Carcinoid tumour; Hepatectomy; Liver metastasis; Neuroendocrine tumour; Survival

Indexed keywords

ALPHA INTERFERON; CISPLATIN; FLUOROURACIL; IODINATED POPPYSEED OIL; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; APPENDIX TUMOR; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIARRHEA; DUODENUM TUMOR; FEMALE; FLUSHING; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; ILEUM TUMOR; LIVER METASTASIS; LIVER RESECTION; MALE; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PANCREAS TUMOR; PATIENT IDENTIFICATION; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDY; SURGICAL PATIENT; SURVIVAL RATE; TUMOR LOCALIZATION; TUMOR RECURRENCE;

EID: 35348931680     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1080/13651820701504199     Document Type: Article

References (45)

1. Norheim, I., Oberg, K., Theodorsson-Norheim, E., Lindgren, PG, Lundqvist, G. and Magnusson, A. (1987) Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg, 206, pp. 115-125.
2. Shebani, KO, Souba, WW, Finkelstein, DM, Stark, PC, Elgadi, KM and Tanabe, KK (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg, 229, pp. 815-821.
3. Ihse, I., Persson, B. and Tibblin, S. (1995) Neuroendocrine metastases of the liver. World J Surg, 19, pp. 76-82.
4. Moertel, CG, Lefkopoulo, M., Lipsitz, S., Hahn, RG and Klaassen, D. (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med, 326, pp. 519-523.
5. Modlin, IM, Lewis, JJ, Ahlman, H., Bilchik, AJ and Kumar, RR (1993) Management of unresectable malignant endocrine tumors of the pancreas. Surg Gynecol Obstet, 176, pp. 507-518.
6. Penn, I. (1991) Hepatic transplantation for primary and metastatic cancers of the liver. Surgery, 110, pp. 726-734.
7. Pichlmayr, R. (1988) Is there a place for liver grafting for malignancy?. Transplant Proc, 20:1, pp. 478-482.
8. Makowka, L., Tzakis, AG, Mazzaferro, V., Teperman, L., Demetris, AJ and Iwatsuki, S. (1989) Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. Surg Gynecol Obstet, 168, pp. 107-111.
9. Bramley, PN, Lodge, JP, Losowsky, MS and Giles, GR. (1990) Treatment of metastatic Vipoma by liver transplantation. Clin Transplant, 4:5, pp. 276-278.
10. Dousset, B., Saint-Marc, O., Pitre, J., Soubrane, O., Houssin, D. and Chapuis, Y. (1996) Metastatic endocrine tumors: Medical treatment, surgical resection, or liver transplantation. World J Surg, 20, pp. 908-914.
11. Dousset, B., Houssin, D., Soubrane, O., Boillot, O., Baudin, F. and Chapuis, Y. (1995) Metastatic endocrine tumors: Is there a place for liver transplantation?. Liver Transpl Surg, 1, pp. 111-117.
12. Alessiani, M., Tzakis, A., Todo, S., Demetris, AJ, Fung, JJ and Starzl, TE (1995) Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg, 180, pp. 1-9.
13. Dominguez, S., Denys, A., Madeira, I., Hammel, P., Vilgrain, V. and Menu, Y. (2000) Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol, 12, pp. 151-157.
14. Eriksson, BK, Larsson, EG, Skogseid, BM, Lofberg, AM, Lorelius, LE and Oberg, KE (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer, 83, pp. 2293-2301.
15. Kim, YH, Ajani, JA, Carrasco, CH, Dumas, P., Richli, W. and Lawrence, D. (1999) Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest, 17, pp. 474-478.
16. Roche, A., Girish, BV, de Baere, T., Baudin, E., Boige, V. and Elias, D. (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol, 13, pp. 136-140.
17. Loewe, C., Schindl, M., Cejna, M., Niederle, B., Lammer, J. and Thurnher, S. (2003) Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol, 180, pp. 1379-1384.
18. McEntee, GP, Nagorney, DM, Kvols, LK, Moertel, CG and Grant, CS (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery, 108, pp. 1091-1096.
19. Grama, D., Eriksson, B., Martensson, H., Cedermark, B., Ahren, B. and Kristoffersson, A. (1992) Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg, 16, pp. 632-639.
20. Ahlman, H., Wangberg, B., Jansson, S., Stenqvist, O., Geterud, K. and Tylen, U. (1991) Management of disseminated midgut carcinoid tumours. Digestion, 49, pp. 78-96.
21. Ahlman, H., Westberg, G., Wangberg, B., Nilsson, O., Tylen, U. and Schersten, T. (1996) Treatment of liver metastases of carcinoid tumors. World J Surg, 20, pp. 196-202.
22. Jaeck, D., Oussoultzoglou, E., Bachellier, P., Lemarque, P., Weber, JC and Nakano, H. (2001) Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: Safe hepatic surgery. World J Surg, 25, pp. 689-692.
23. Que, FG, Nagorney, DM, Batts, KP, Linz, LJ and Kvols, LK. (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg, 169, pp. 36-42.
24. Malik, HZ, Hamady, ZZ, Adair, R., Finch, R., Al-Mukhtar, A. and Toogood, GJ (2007) Prognostic influence of multiple hepatic metastases from colorectal cancer. Eur J Surg Oncol, 33, pp. 468-473.
25. Menon, KV, Al-Mukhtar, A., Aldouri, A., Prasad, RK, Lodge, PA and Toogood, GJ (2006) Outcomes after major hepatectomy in elderly patients. J Am Coll Surg, 203, pp. 677-683.
26. Hamady, ZZ, Malik, HZ, Finch, R., Adair, R., Al-Mukhtar, A. and Prasad, KR (2006) Hepatic resection for colorectal metastasis: Impact of tumour size. Ann Surg Oncol, 13, pp. 1493-1499.
27. Nishio, H. (2007) Outcome following repeat liver resection for colorectal liver metastases. Eur J Surg Oncol
28. Gomez, D., Al-Mukhtar, A., Toogood, GJ, Lodge, JPA and Prasad, KR (2007) Aggressive surgical resection for the management of hepatic metastases from gastrointestinal stromal tumours: A single centre experience. HPB, 9, pp. 64-70.
29. Chamberlain, RS, Canes, D., Brown, KT, Saltz, L., Jarnagin, W. and Fong, Y. (2000) Hepatic neuroendocrine metastases: Does intervention alter outcomes?. J Am Coll Surg, 190, pp. 432-445.
30. Sarmiento, JM, Heywood, G., Rubin, J., Ilstrup, DM, Nagorney, DM and Que, FG (2003) Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg, 197, pp. 29-37.
31. Yao, KA, Talamonti, MS, Nemcek, A., Angelos, P., Chrisman, H. and Skarda, J. (2001) Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery, 130, pp. 677-682.
32. Chen, H., Hardacre, JM, Uzar, A., Cameron, JL and Choti, MA. (1998) Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival?. J Am Coll Surg, 187, pp. 88-92.
33. Nave, H., Mossinger, E., Feist, H., Lang, H. and Raab, H. (2001) Surgery as primary treatment in patients with liver metastases from carcinoid tumors: A retrospective, unicentric study over 13 years. Surgery, 129, pp. 170-175.
34. Thompson, GB, van Heerden, JA, Grant, CS, Carney, JA and Ilstrup, DM (1988) Islet cell carcinomas of the pancreas: A twenty-year experience. Surgery, 104, pp. 1011-1017.
35. Fenwick, SW, Wyatt, JI, Toogood, GJ and Lodge, JP (2004) Hepatic resection and transplantation for primary carcinoid tumors of the liver. Ann Surg, 239, pp. 210-219.
36. Clancy, TE, Sengupta, TP, Paulus, J., Ahmed, F., Duh, MS and Kulke, MH (2006) Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci, 51, pp. 877-884.
37. Venzon, DJ, Serrano, J., Goebel, SU, Doppman, JL and Gibril, F. (1999) Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol, 17, pp. 615-630.
38. Maton, PN, Gardner, JD and Jensen, RT (1989) Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci, 34:3, pp. 28S-39S.
39. Clements, D. and Elias, E. (1985) Regression of metastatic vipoma with somatostatin analogue SMS 201-995. Lancet, 1, pp. 874-875.
40. Frank, M., Klose, KJ, Wied, M., Ishaque, N., Schade-Brittinger, C. and Arnold, R. (1999) Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol, 94, pp. 1381-1387.
41. Arnold, R., Neuhaus, C., Benning, R., Schwerk, WB, Trautmann, ME and Joseph, K. (1993) Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg, 17, pp. 511-519.
42. Saltz, L., Trochanowski, B., Buckley, M., Heffernan, B., Niedzwiecki, D. and Tao, Y. (1993) Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer, 72, pp. 244-248.
43. Arnold, R., Trautmann, ME, Creutzfeldt, W., Benning, R., Benning, M. and Neuhaus, C. (1996) Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut, 38, pp. 430-438.
44. Faiss, S., Rath, U., Mansmann, U., Caird, D., Clemens, N. and Riecken, EO (1999) Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion, 60, pp. 469-476.
45. Faiss, S., Pape, UF, Bohmig, M., Dorffel, Y., Mansmann, U. and Golder, W. (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol, 21, pp. 2689-2696.